Systematic review of measurement properties of liver cancer patient specific self-reported outcome assessment tools

doi:10.3761/j.issn.0254-1769.2024.22.007

Abstract

Abstract:

Objective To systematically evaluate the measurement properties and methodological quality of the liver cancer patients specific self-reported outcome assessment tools，and to provide a basis for healthcare professionals to select a high-quality scale. Methods Systematic search of PubMed，Embase，CINAHL，Web of Science，Cochrane Library，China National Knowledge Infrastructure，VIP Database，Wanfang Database，and China Biomedical Literature Database was conducted for studies related to the evaluation of the measurement properties of liver cancer specific self-reported outcome assessment tools. The search period was from the date of creation to February 1，2024，and 2 researchers independently conducted literature screening and data extraction according to the COSMIN selection criteria，and used the COSMIN Risk of Bias Inventory and Quality Criteria Scale to measure the methodological quality and measurement properties，and the final recommendations were formed. Results A total of 12 studies involving 8 specific self-reported outcome assessment tools for liver cancer patients were included. Finally，TSM-PLC was recommended at level A；EORTC QLQ-HCC18，QOL-LC，QLICP-LI were recommended at level C；FACT-HEP，MDASI-Periop-Hep，Quality of Life Scale for Liver Cancer Patients，and FHSI-8 were recommended at level B. Conclusion Compared to other scales，TSM-PLC has relatively good methodological quality and measurement properties，and is recommended for use as a priority. Due to its evaluation content mainly focusing on the patient’s physical symptom distress，it can be used in conjunction with other scales to enhance the comprehensiveness of the evaluation.

Key words: Liver Neoplasms, Self-Reporting, Assessment Tools, Measurement Properties, System Evaluation, Evidence-Based Nursing

摘要：

目的系统评价肝癌患者特异性自我报告结局评估工具的测量学属性及其方法学质量，为医护人员选择最佳评估工具提供依据。方法系统检索PubMed、Embase、CINAHL、Web of Science、Cochrane Library、中国知网、维普数据库、万方数据库及中国生物医学文献数据库中与肝癌患者特异性自我报告结局评估工具相关的研究，检索时限为建库至2024年2月1日。2名研究者独立进行文献筛选和资料提取，采用基于共识的健康测量工具遴选标准（consensus-based standards for the selection of health measurement instruments，COSMIN）偏倚风险清单及其质量标准，评定纳入研究的方法学质量及测量学属性，并形成推荐意见。结果共纳入12篇文献，涉及8个肝癌患者特异性自我报告结局评估工具。通过评估，肝癌患者特异性症状模块问卷为A级推荐，癌症治疗功能评价系统-肝胆量表、肝癌围手术期症状报告问卷、肝癌患者生命质量量表、癌症治疗的功能评估-肝胆症状指数问卷为B级推荐，欧洲癌症研究与治疗组织肝细胞癌患者特异性生活质量问卷、肝癌患者生活质量评定量表、癌症患者生命质量测定量表体系之肝癌量表为C级推荐。结论肝癌患者特异性症状模块问卷的方法学质量及测量学属性相对较好，优先推荐应用。由于评估内容主要聚焦于患者的身体症状困扰，可与其他评估工具联合使用，以提高评估的全面性。

关键词: 肝癌, 自我报告, 评估工具, 测量学属性, 系统评价, 循证护理学

LU Shiyan, LIU Xian, JIANG Xiaoxiao, HUANG Yanping, XU Hongxia. Systematic review of measurement properties of liver cancer patient specific self-reported outcome assessment tools[J]. Chinese Journal of Nursing, 2024, 59(22): 2734-2741.

陆诗燕, 刘羡, 江笑笑, 黄燕萍, 徐虹霞. 肝癌患者特异性自我报告结局评估工具测量学属性的系统评价[J]. 中华护理杂志, 2024, 59(22): 2734-2741.

Figures/Tables 3

References 28

[1]	Xia C, Dong X, Li H, et al. Cancer statistics in China and United States,2022:profiles,trends,and determinants[J]. Chin Med J(Engl), 2022, 135(5):584-590.
[2]	Anwanwan D, Singh SK, Singh S, et al. Challenges in liver cancer and possible treatment approaches[J]. Biochim Biophys Acta Rev Cancer, 2020, 1873(1):188314.
[3]	王观宇. 肝癌转化治疗的策略和现状[J]. 临床外科杂志, 2021, 29(11):1012-1014.
	Wang GY. Strategies and current status of conversion therapy for liver cancer[J]. J Clin Surg, 2021, 29(11):1012-1014.
[4]	邓燕英, 王爱妹, 刘沛珍, 等. 原发性肝癌术后患者癌症复发恐惧及影响因素研究[J]. 护理学杂志, 2019, 34(8):18-21.
	Deng YY, Wang AM, Liu PZ, et al. Fear of cancer recurrence and its influencing factors among postoperative patients with primary liver cancer[J]. J Nurs Sci, 2019, 34(8):18-21.
[5]	Firkins J, Hansen L, Driessnack M, et al. Quality of life in “chronic” cancer survivors:a meta-analysis[J]. J Cancer Surviv, 2020, 14(4):504-517. DOI PMID
[6]	孟祥敏, 王倩, 闫荣, 等. 结直肠癌患者报告结局评估工具及临床应用的研究进展[J]. 中华护理杂志, 2022, 57(9):1094-1099. DOI URL
	Meng XM, Wang Q, Yan R, et al. Research progress on assessment tools of patient-reported outcomes for colorectal cancer patients and the clinical application[J]. Chin J Nurs, 2022, 57(9):1094-1099. DOI URL
[7]	Gabriele E, Spooner R, Brewer R, et al. Dissociations between self-reported interoceptive accuracy and attention:evidence from the Interoceptive Attention Scale[J]. Biol Psychol, 2022, 168:108243.
[8]	成磊, 张雯, 黄青梅, 等. 患者自我报告结局在癌症患儿照护领域的应用研究进展[J]. 中华护理杂志, 2020, 55(8):1174-1178. DOI URL
	Cheng L, Zhang W, Huang QM, et al. Patient reported outcomes in pediatric cancer care:application and research progress[J]. Chin J Nurs, 2020, 55(8):1174-1178.
[9]	Prinsen C, Mokkink LB, Bouter LM, et al. COSMIN guideline for systematic reviews of patient-reported outcome measures[J]. Qual Life Res, 2018, 27(5):1147-1157. DOI PMID
[10]	Mokkink LB, Prinsen CA, Bouter LM, et al. The COnsensus-based Standards for the selection of health Measurement INstruments(COSMIN) and how to select an outcome measurement instrument[J]. Braz J Phys Ther, 2016, 20(2):105-113.
[11]	Mokkink LB, de Vet H, Prinsen C, et al. COSMIN risk of bias checklist for systematic reviews of patient-reported outcome measures[J]. Qual Life Res, 2018, 27(5):1171-1179. DOI PMID
[12]	Terwee CB, Prinsen C, Chiarotto A, et al. COSMIN methodology for evaluating the content validity of patient-reported outcome measures:a Delphi study[J]. Qual Life Res, 2018, 27(5):1159-1170. DOI PMID
[13]	Alhazzani W, Guyatt G. An overview of the GRADE approach and a peek at the future[J]. Med J Aust, 2018, 209(7):291-292. PMID
[14]	Heffernan N, Cella D, Webster K, et al. Measuring health-related quality of life in patients with hepatobiliary cancers:the functional assessment of cancer therapy-hepatobiliary questionnaire[J]. J Clin Oncol, 2002, 20(9):2229-2239. DOI PMID
[15]	朱兆承, 郎庆波, 陈喆, 等. 肝胆肿瘤治疗功能评定量表中文版的考评[J]. 中西医结合学报, 2008, 6(4):341-345.
	Zhu ZC, Lang QB, Chen Z, et al. Evaluation of the Chinese version of the Hepatobiliary Tumor Treatment Function Rating Scale[J]. J Chin Integr Med, 2008, 6(4):341-345.
[16]	Blazeby JM, Currie E, Zee BC, et al. Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma,the EORTC QLQ-HCC18[J]. Eur J Cancer, 2004, 40(16):2439-2444. DOI PMID
[17]	Serrano D, Podger L, Barnes G, et al. Psychometric validation of the EORTC QLQHCC 18 in patients with previously treated unresectable hepatocellular carcinoma[J]. Qual Life Res, 2022, 31(3):937-950.
[18]	Mikoshiba N, Tateishi R, Tanaka M, et al. Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module(QLQ-HCC18)[J]. Health Qual Life Outcomes, 2012, 10:58.
[19]	Yang Z, Wan C, Li W, et al. Development and validation of the Simplified Chinese Version of EORTC QLQ-HCC18 for patients with hepatocellular carcinoma[J]. Cancer In Vest, 2015, 33(8):340-346.
[20]	Wan C, Fang J, Yang Z, et al. Development and validation of a quality of life instrument for patients with liver cancer QOL-LC[J]. Am J Clin Oncol, 2010, 33(5):448-455.
[21]	王毅欣. 原发性肝癌患者自我效能感在其症状群与生活质量间的作用模型研究[D]. 上海: 第二军医大学, 2012.
	Wang YX. A model of self-efficacy in patients with primary liver cancer on the relationship between symptom clusters and quality of life[D]. Shanghai: Second Military Medical University, 2012.
[22]	Wang XS, Shi Q, Williams LA, et al. Development of a patient-reported outcome tool for assessing symptom burden during perioperative care in liver surgery:the MDASI-PeriOp-Hep[J]. Eur J Oncol Nurs, 2021, 52:101959.
[23]	李微. 癌症患者生命质量测定量表体系之肝癌量表QLICP-LI的研制与初步应用[D]. 昆明: 昆明医科大学, 2013.
	Li W. Development and preliminary applications of the quality of life instrument for cancer patients-liver cancer[D]. Kunming: Kunming Medical University, 2013.
[24]	孙菁, 郭强. 原发性肝癌生命质量量表的制定与评价[J]. 解放军医院管理杂志, 2006, 13(2):141-143.
	Sun J, Guo Q. Development and evaluation of quality of life scale for primary liver cancer[J]. Med J Chin PLA, 2006, 13(2):141-143.
[25]	Yount S, Cella D, Webster K, et al. Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers:the FACT Hepatobiliary Symptom Index[J]. J Pain Symptom Manage, 2002, 24(1):32-44.
[26]	彭健, 沈蓝君, 陈祎婷, 等. COSMIN-RoB清单简介及测量工具内部结构研究的偏倚风险清单解读[J]. 中国循证医学杂志, 2020, 20(10):1234-1240.
	Peng J, Shen LJ, Chen YT, et al. An overview of the COSMIN-RoB checklist and the interpretation of it in evaluating the risk of bias of studies on internal structure[J]. Chin J Evid Based Med, 2020, 20(10):1234-1240.
[27]	Güneş F, Boyraz S. Effect of Atrial Fibrillation on Quality of Life(AFEQT) Questionnaire:a Turkish validity and reliability study[J]. Turk Kardiyol Dern Ars, 2021, 49(3):223-232.
[28]	高云, 赵俊峰, 徐丽丽, 等. COSMIN 操作指南对中文版电子健康素养量表的评价[J]. 中国老年学杂志, 2020, 40(9):1968-1973.
	Gao Y, Zhao JF, Xu LL, et al. Evaluation of the Chinese version of the electronic health literacy scale in the COSMIN operation guide[J]. Chin J Gerontol, 2020, 40(9):1968-1973.